Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Racial and rural-urban disparities in radiotherapy utilization for oral cavity and pharyngeal cancers: A SEER analysis from 2013-2022.

Ahmed Bashir Sukhera, Daniyaal Ahmad, Aimen Dar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18101

e18101 Background: Head and neck cancers accounted for 1,464,550 new cases and 487,993 deaths across the world in 2020 and...

Defining a long-term benefit phenotype to PD-1 inhibitors in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A multicentre retrospective study.

Justin Panasci, Shree Patel, Marco Iafolla et al. Jun 01, 2026 pp. 6050-6050 10.1200/jco.2026.44.16_suppl.6050

6050 Background: Limited data exists on predictors of durable benefit to PD-1 inhibitors in R/M HNSCC. We aimed to identif...

Reevaluating the comparative effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RA) vs aspirin for colorectal cancer prevention in type 2 diabetes.

Junmin Song, Yue Li, Wing Fai Li et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15690

e15690 Background: Recent studies suggest that aspirin and GLP-1RA may reduce the risk of colorectal cancer (CRC). A recen...

Comparison of baseline gut microbiome features between response subgroups of patients (pts) with advanced melanoma undergoing immune checkpoint inhibitor (ICI) therapy.

Michelle Ferreira, Kimberly Peloza, James R. White et al. Jun 01, 2026 pp. 9528-9528 10.1200/jco.2026.44.16_suppl.9528

9528 Background: Gut microbiome composition has been implicated as a potential biomarker of response to ICIs in melanoma p...

Penpulimab (AK105) combined with cetuximab as first-line treatment in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial.

Shu Tian, Qin Zhao, Xin Jiang et al. Jun 01, 2026 pp. 6029-6029 10.1200/jco.2026.44.16_suppl.6029

6029 Background: Combination therapy with PD-1 and EGFR inhibitors has shown promising efficacy in recurrent/metastatic he...

Paired urine and plasma ctDNA profiling to enable longitudinal molecular monitoring during HER2 ADC bladder preserving therapy in muscle-invasive bladder cancer (HOPE03).

Jiani Deng, Feng Wen, Haoran Tang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16608

e16608 Background: Although trimodal therapy is the standard organ-preserving approach for muscle-invasive bladder cancer...

Development of payload-resistant human ovarian cancer cell lines to better understand antibody-drug conjugate sequencing and resistance mechanisms.

Janina Pearce, Payton De La Cruz, Samantha Buyungo et al. Jun 01, 2026 pp. 5549-5549 10.1200/jco.2026.44.16_suppl.5549

5549 Background: Within gynecologic oncology, limited data exist regarding mechanisms of resistance to antibody-drug-conju...

A preventable cancer with unequal outcomes: Cervical cancer disparities in Wisconsin, 2014–2021.

Rushabh Shah, Yuhong Zhou, Kirsten M. Beyer Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22595

e22595 Background: Cervical cancer remains a preventable cause of morbidity and mortality in the United States, with avail...

Metformin use and outcomes among breast cancer patients on immunotherapy: Insights from a real-world cohort.

Kevin H. Kensler, Faith Morley, Sadna Budhu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23086

e23086 Background: An obesity-related cancer, 1 in 3 adults with breast cancer have preexisting type 2 diabetes (T2D) at d...

A phase 1a/b study of RGT-61159, an oral MYB splicing modulator, in patients with advanced adenoid cystic carcinoma and colorectal cancer.

Alan Loh Ho, Enrique Sanz Garcia, Renata Ferrarotto et al. Jun 01, 2026 pp. 3089-3089 10.1200/jco.2026.44.16_suppl.3089

3089 Background: MYB is a master regulator of cell proliferation, self-renewal, and differentiation processes and its aber...

A phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data.

Hong Jae Chon, Jung Yong Hong, Xueli Bai et al. Jun 01, 2026 pp. 3016-3016 10.1200/jco.2026.44.16_suppl.3016

3016 Background: GPC3 is a tumor-specific antigen that is highly expressed in hepatocellular carcinoma (HCC) and squamous...

Remote physical activity intervention for young Hispanic breast cancer survivors with persistent post-surgical pain.

Stephanie Rosenberg, Tawny Boyce, Cindy K. Blair et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12699

e12699 Background: Young breast cancer survivors frequently experience persistent post-breast surgery pain syndrome (PBSPS...

A phase I/II study of safety/efficacy using lurbinectedin, combined with ipilimumab, and nivolumab, for advanced soft tissue sarcomas (NCT05876715).

Samantha Jeffrey, Sant P. Chawla, Oliver Davidorf et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps11599

TPS11599 Background: Soft tissue sarcoma (STS) cells exhibit heightened immunogenicity during the early stages of the dise...

Comparative effectiveness of first-/second-generation EGFR-TKI combination therapy versus third-generation EGFR-TKI monotherapy in previously untreated advanced <i>EGFR</i> -mutant NSCLC: A real-world, retrospective study in China.

Wei Zhang, Xinwei Wu, Danni Wang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20726

e20726 Background: At present, third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs)...

Impact of anemia on real-world outcomes in myelofibrosis: A propensity-matched analysis.

Kanishka Uttam Chandani, Jatin Thukral, Riya Shah et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18609

e18609 Background: Anemia is a frequent complication of myelofibrosis (MF) and is embedded in widely used prognostic syste...

Prevalence and clinical significance of AR-V7 in extra-prostatic malignancies: A systematic review.

Semir Vranic, Zaineh Alnoubani, Youssuf Khanafer et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15181

e15181 Background: Androgen receptor splice variant 7 ( AR-V7 ) is a constitutivel...

Analyzing hydroxymethylglutaryl-CoA synthase 2 (HMGCS2) expression and survival in patients with hepatocellular carcinoma (HCC) using cBioPortal.

Andrew Irving Hearn, Ronald Christopher Roberts, Tyler Ryan Ellett Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16236

e16236 Background: The ketogenic diet (KD) has been shown to up-regulate the rate-limiting enzyme of ketogenesis (Lan, 202...

Evaluating the impact of multi-level interventions on immunohistochemistry uptake in breast cancer patients in Nigeria: A retrospective cross-sectional study.

Ria Subramanian, Kahaan Shah, Abiola Falilat Ibraheem Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13639

e13639 Background: Breast cancer (BCA) is the most common malignancy globally, with highest mortality in Sub-Saharan Afric...

Advancing equity in precision oncology: Impact of in-house NGS for NSCLC in a safety-net hospital.

Lilin Tong, Dylan Tran, Corina Beiner et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20704

e20704 Background: Next-generation sequencing (NGS) is essential for NSCLC management, yet access remains inequitable. We...

Comparative safety of immune checkpoint inhibitor–chemotherapy regimens across multiple tumor types: A systematic review and network meta-analysis.

Yiyue Xu, Butuo Li, Aiqin Gao et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14571

e14571 Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy have become standard first-line treatmen...

Impact of electronic patient-reported outcome measure (ePROM)–triggered, collaborative care (CC)–based symptom intervention on depression and anxiety in young adults (YAs) with cancer.

Michael H. Storandt, Zhaohui Jin, Kathryn Jean Ruddy et al. Jun 01, 2026 pp. 12007-12007 10.1200/jco.2026.44.16_suppl.12007

12007 Background: YAs with cancer, defined as those diagnosed prior to the age of 40, may experience greater symptom burde...

Impact of bevacizumab on the efficacy of antibody–drug conjugates as later-line treatment of basal-like immune-suppressed triple-negative breast cancer.

Yin Liu, Fan Yang, Wenjia Zuo et al. Jun 01, 2026 pp. 1020-1020 10.1200/jco.2026.44.16_suppl.1020

1020 Background: Basal-like immune-suppressed (BLIS) triple-negative breast cancer (TNBC) is associated with a poor progno...

AQUARIUS: A longitudinal multi-center molecular biomarker discovery registry for patients with hematologic malignancies.

Michael A. Thompson, Mitchell Reed Smith, Mehrdad Mobasher et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps7105

TPS7105 Background: Despite therapeutic innovations over the past decade in hematologic malignancies, there remains a sign...

A digital health intervention to enhance well-being among adolescent and young adult survivors of cancer: Results from the EMPOWER full factorial trial.

John M. Salsman, Karly M. Ingram, Elizabeth Addington et al. Jun 01, 2026 pp. 12006-12006 10.1200/jco.2026.44.16_suppl.12006

12006 Background: Adolescent and young adult (AYA) survivors of cancer are at significant risk of adverse psychological ou...

Genome-wide association and Mendelian randomization analyses of body mass index and breast cancer risk in women of African ancestry.

Wenji Guo, James L. Li, Yijia Sun et al. Jun 01, 2026 pp. 10598-10598 10.1200/jco.2026.44.16_suppl.10598

10598 Background: The relationship between adiposity and breast cancer risk is complex and incompletely understood, partic...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page